Individualized, Heterologous Chimpanzee Adenovirus And Self-Amplifying Mrna Neoantigen Vaccine For Advanced Metastatic Solid Tumors: Phase 1 Trial Interim Results

Palmer, C.D., Rappaport, A.R., Davis, M.J., Hart, M.G., Scallan, C.D., Hong, S-J, Gitlin, L., Kraemer, L.D., Kounlavouth, S., Yang, A., Smith, L., Schenk, D., Skoberne, M., Taquechel, K., Marrali, M., Jaroslavsky,J.R., Nganje, C.N., Maloney, E., Zhou, R., Navarro-Gomez, D., Greene, A.C., Grotenbreg, G., Greer, R., Blair, W., Cao, M.D., Chan, S., Bae, K., Spira, A.I., Roychowdhury, S., Carbone, D.P., Henick, B.S., Drake, C.G., Solomon, B.J., Ahn, D.H., Mahipal, A., Maron, S.B., Johnson, B., Rousseau, R., Yelensky, R., Liao, C-Y, Catenacci, D.V.T., Allen, A, Ferguson, A.R., and Jooss, K. Individualized, Heterologous Chimpanzee Adenovirus And Self-Amplifying Mrna Neoantigen Vaccine For Advanced Metastatic Solid Tumors: Phase 1 Trial Interim Results. Nature Medicine. 2022, 28:1619–1629. Aug-22.